- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Nelfinavir mesylate
- Drug
- Lead sponsor
- Agouron Pharmaceuticals
- Industry
- Eligibility
- 13 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Orange, California • San Diego, California + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2113–2136
of 2,669
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lumbar Spine Disease
- Interventions
- Irrisept Irrigation solution
- Device
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Breast Cancer
- Interventions
- Basic public reporting, Enhanced intervention, Control group - observational
- Behavioral
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 400,415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Muscle Weakness, ICU-acquired Weakness
- Interventions
- HMB protein supplement (3g), Nutritional Supplement
- Dietary Supplement
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 65 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Malignant Female Reproductive System Neoplasm
- Interventions
- Hydromorphone, Laparotomy, Liposomal Bupivacaine, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Glioblastoma Multiforme, Gliosarcoma
- Interventions
- ZD6474, temozolomide, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Patrick Y. Wen, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer
- Interventions
- Gemcitabine with escalating ascorbic acid
- Drug
- Lead sponsor
- Joseph J. Cullen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Chronic Low Back Pain
- Interventions
- Pregnenolone, DHEA, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Dengue
- Interventions
- Pre-transfection F17, Post-transfection F17, Post-transfection F19, Placebo
- Biological · Other
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation
- Interventions
- Rivaroxaban 2.5 mg Tablet
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia
- Interventions
- Low Dose ICA-17043, High dose ICA-17043, Placebo
- Drug
- Lead sponsor
- Icagen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Oakland, California • San Francisco, California + 16 more
- Conditions
- Pemphigus
- Interventions
- Infliximab, Placebo Comparator
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Iowa City, Iowa • Durham, North Carolina + 1 more
- Conditions
- Breast Cancer
- Interventions
- Mifepristone, Placebo, Nab-Paclitaxel
- Drug · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Evanston, Illinois + 2 more
- Conditions
- Cystic Fibrosis
- Interventions
- KB001, Placebo
- Biological · Other
- Lead sponsor
- Humanigen, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Stanford, California • Aurora, Colorado + 8 more
- Conditions
- Malignant Neoplasm
- Interventions
- Best Practice, Laboratory Biomarker Analysis, Oculus Rift Headset, Questionnaire Administration
- Other · Device
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Sunitinib Malate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 484
- States / cities
- Anniston, Alabama • Mobile, Alabama • Little Rock, Arkansas + 321 more
- Conditions
- Low Back Pain
- Interventions
- Adhesiolysis
- Procedure
- Lead sponsor
- Pain Management Center of Paducah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Paducah, Kentucky
- Conditions
- Alcohol Consumption
- Interventions
- Brief Alcohol Intervention, Lifestyle brochures
- Behavioral · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
- Interventions
- Cabozantinib, Best Supportive Care (BSC)
- Drug · Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 5 Years to 30 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Malignant Skin Neoplasm
- Interventions
- Mohs Surgery, Internet-Based Intervention, Telephone-Based Intervention, Educational Intervention, Exercise Intervention, Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment, Questionnaire Administration, Survey Administration
- Procedure · Other · Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Melanoma
- Interventions
- Ipilimumab, Corticosteroid: Betamethasone, Corticosteroid: Dexamethasone, Corticosteroid: Fludrocortisone, Corticosteroid: Hydrocortisone, Corticosteroid: Meprednisone, Corticosteroid: Methylprednisolone, Corticosteroid: Prednisolone, Corticosteroid: Prednisone, Corticosteroid: Triamcinolone
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 11 more
- Conditions
- Oral Cavity Neoplasm, Oropharyngeal Neoplasm, Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7, Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet, Pharmacological Study, Placebo
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Minneapolis, Minnesota • Rochester, New York + 1 more
- Conditions
- Pulmonary Fibrosis, Pulmonary Hypertension
- Interventions
- Iloprost Inhalation Solution (Ventavis)
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
- Conditions
- Chronic Kidney Disease (Stages 4 and 5)
- Interventions
- Kidney RISE
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • New York, New York